search
Back to results

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

Primary Purpose

Sepsis

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Doripenem
Sponsored by
Emory University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis focused on measuring Pharmacokinetics, Pharmacodynamics, Doripenem, Trauma, sepsis, Trauma patients with sepsis

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients are 18 years of age or older
  • Admitted to Emory surgical intensive care unit (ICU) service
  • Have a diagnosis of sepsis that requires empiric antimicrobial therapy
  • Obtained written informed consent from the patient or a first-degree relative if the patient is unable to give informed consent due to his/her medical condition prior to initiation of any study procedure

Exclusion Criteria:

  • Surgical ICU length of stay less than 24 hours
  • Acute or chronic renal dysfunction (urine output less than 0.5 mL/kg/hr or calculated creatinine clearance of less than 50 mL/min)
  • Pregnancy
  • Known allergy to beta-lactam antibiotics
  • Non-English-speaking patients

Sites / Locations

  • Grady Memorial Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Doripenem group

Arm Description

Patients will receive doripenem for the treatment of their infection

Outcomes

Primary Outcome Measures

Volume of Distribution (Vd)
The Volume of distribution is the calculated volume that the given amount of drug is uniformly distributed in the body to achieve a particular concentration
Clearance (CL)
Clearance is the volume of drug removed from the body per unit of time (hrs).
Elimination Constant (ke)
The elimination rate constant of a drug from the central compartment

Secondary Outcome Measures

Full Information

First Posted
December 8, 2009
Last Updated
December 19, 2013
Sponsor
Emory University
Collaborators
Ortho-McNeil Janssen Scientific Affairs, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01027897
Brief Title
Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients
Official Title
Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients With Sepsis at Grady Health System
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Emory University
Collaborators
Ortho-McNeil Janssen Scientific Affairs, LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study hypothesis is to measure how the drug doripenem is cleared from the body of critically ill trauma patients. The investigators will measure blood drug concentrations and calculate how much the drug distributes in the body and how fast it is removed from the body. There is little information on how drugs are cleared in critically ill patients and the wrong dose of a drug could make it ineffective. The investigators will use this information to predict the most reasonable dose to treat infections effectively in these patients.
Detailed Description
Understanding the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of an antibiotic can provide insight into developing appropriate dosing regimens. It is even more imperative at the present time to maximize PK/PD parameters since there are no new novel antimicrobial agents to treat resistant gram-negative infections. This approach allows us to achieve superior PD parameters and treat bacteria that would have been resistant to standard dosing due to higher minimum inhibitory concentrations (MICs). Doripenem exhibits time-dependent bactericidal activity and the pharmacodynamic parameter predicting clinical and bacteriologic outcomes is the percentage of the dosing interval that free drug concentrations remain above the minimum inhibitory concentration (T > MIC) of the infecting pathogen Sepsis is known to influence drug pharmacokinetics and pharmacodynamics as a result of changes in hemodynamics, capillary permeability, third spacing, acid-base status, serum proteins, and organ function. Moreover, trauma patients tend to be younger with fewer comorbidities. They are hypermetabolic and are often given aggressive fluid resuscitation resulting in increased renal clearance of drugs and a larger volume of distribution. As a consequence of these differences in PK parameters, the calculated PD parameters will likely differ resulting in sub-optimal T> MIC. For time-dependent antibacterial agents such as doripenem, the T > MIC is one of the most important pharmacodynamic parameters in predicting clinical efficacy, therefore it is imperative to evaluate the PK parameters in this particular population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
Keywords
Pharmacokinetics, Pharmacodynamics, Doripenem, Trauma, sepsis, Trauma patients with sepsis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Doripenem group
Arm Type
Experimental
Arm Description
Patients will receive doripenem for the treatment of their infection
Intervention Type
Drug
Intervention Name(s)
Doripenem
Intervention Description
Doripenem 1 gm administered over 4 hours X 3 doses
Primary Outcome Measure Information:
Title
Volume of Distribution (Vd)
Description
The Volume of distribution is the calculated volume that the given amount of drug is uniformly distributed in the body to achieve a particular concentration
Time Frame
After 3rd dose of study medication
Title
Clearance (CL)
Description
Clearance is the volume of drug removed from the body per unit of time (hrs).
Time Frame
After 3rd dose of study medication
Title
Elimination Constant (ke)
Description
The elimination rate constant of a drug from the central compartment
Time Frame
after 3rd dose of study drug

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients are 18 years of age or older Admitted to Emory surgical intensive care unit (ICU) service Have a diagnosis of sepsis that requires empiric antimicrobial therapy Obtained written informed consent from the patient or a first-degree relative if the patient is unable to give informed consent due to his/her medical condition prior to initiation of any study procedure Exclusion Criteria: Surgical ICU length of stay less than 24 hours Acute or chronic renal dysfunction (urine output less than 0.5 mL/kg/hr or calculated creatinine clearance of less than 50 mL/min) Pregnancy Known allergy to beta-lactam antibiotics Non-English-speaking patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Salomone, MD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Grady Memorial Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30303
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

We'll reach out to this number within 24 hrs